Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
In the transition from normal glucose tolerance (NGT) to type 2 diabetes mellitus (T2DM), the role of β-cell dysfunction and peripheral insulin resistance (IR) is well established. However, the impact of dysfunctional adipose tissue has not been fully elucidated. The aim of this study was to evaluate the role of resistance to the antilipolytic effect of insulin (adipose tissue IR [Adipo-IR]) in a large group of subjects with NGT, impaired glucose tolerance (IGT), and T2DM. Three hundred two subjects with varying glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insulin clamp. We evaluated Adipo-IR (fasting and mean OGTT plasma free fatty acid [FFA] × insulin concentrations), peripheral IR (1/[Matsuda index] and (M/I)−1 value), and β-cell function (calculated as the ratio of the increment in plasma insulin to glucose [OGTT/IR (ΔI/ΔG ÷ IR)]). Fasting Adipo-IR was increased twofold in obese subjects with NGT and IGT versus lean subjects with NGT (8.0 ± 1.1 and 9.2 ± 0.7 vs. 4.1 ± 0.3, respectively) and threefold in subjects with T2DM (11.9 ± 0.6; P < 0.001). Progressive decline in ΔI/ΔG ÷ IR was associated with a progressive impairment in FFA suppression during OGTT, whereas the rise in mean plasma glucose concentration only became manifest when subjects became overtly diabetic. The progressive decline in β-cell function that begins in individuals with NGT is associated with a progressive increase in FFA and fasting Adipo-IR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the presence of Adipo-IR, FFA release is not suppressed despite high insulin concentrations.45”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [45]
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“Data Analysis Insulin sensitivity was assessed by Matsuda index (32) from the plasma glucose and insulin concentrations measured during the OGTT.”
MethodSelf-citationAdipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743 · cited 1×
“Thus, with progression from lean NGT to obese NGT to IGT, the insulin secretion/insulin resistance (disposition) index declined and was closely related to the deterioration in OGTT, consistent with previous studies from our group and others (31,34,39,40).”
ResultMechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539 · cited 1×
“, the impaired suppression of lipolysis in the presence of high insulin levels, has been associated with glucose intolerance, and elevated plasma FFA have been shown to impair muscle insulin signaling, promote hepatic gluconeogenesis, and impair glucose-stimulated insulin response (7-13).”
BackgroundScherer, P. E. (2006) · Diabetes · doi:10.2337/db06-0263 · Cited by 1,066
Effect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050 · cited 1×
“, the impaired suppression of lipolysis in the presence of high insulin levels, has been associated with glucose intolerance, and elevated plasma FFA have been shown to impair muscle insulin signaling, promote hepatic gluconeogenesis, and impair glucose-stimulated insulin response (7-13).”
BackgroundSelf-citationFatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896 · cited 1×
“In contrast to the OGTT, studies with the stepped hyperinsulinemic clamp consistently have demonstrated impaired suppression of plasma FFA and glycerol concentrations and (14)C-palmitate turnover (18,22,24) (i.”
ResultBoden, G. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.007 · Cited by 853 · cited 1×
“Insulin acts on adipose tissue 1) by stimulating glucose uptake and triglyceride synthesis and 2) by suppressing triglyceride hydrolysis and release of FFA and glycerol into the circulation (6,7).”
BackgroundGroop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 4×
“In contrast to the OGTT, studies with the stepped hyperinsulinemic clamp consistently have demonstrated impaired suppression of plasma FFA and glycerol concentrations and (14)C-palmitate turnover (18,22,24) (i.”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Items 101–200 of 346
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Trouwborst, I., Goossens, G. H., Astrup, A., Saris, W. H. M., & Blaak, E. E. (2021) · Nutrients · doi:10.3390/nu13051588 · Cited by 31
Engin, B., Willis, S. A., Malaikah, S., Sargeant, J. A., Yates, T., Gray, L. J., Aithal, G. P., Stensel, D. J., & King, J. A. (2022) · Obesity Reviews · doi:10.1111/obr.13445 · Cited by 31
Zeng, J., Zhang, T., Yang, Y. C., Wang, J., Zheng, D., Hou, Y., Tong, Y., Fan, X., Wang, X., & Fang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369600 · Cited by 33
Integrative phenotyping of glycemic responders upon clinical weight loss using multi-omics
Valsesia, A., Chakrabarti, A., Hager, J., Langin, D., Saris, W. H. M., Astrup, A. V., Blaak, E. E., Viguerie, N., & Masoodi, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65936-8 · Cited by 31
Queathem, E. D., Welly, R. J., Clart, L., Rowles, C. C., Timmons, H., Fitzgerald, M., Eichen, P. A., Lubahn, D. B., & Vieira‐Potter, V. J. (2021) · Cells · doi:10.3390/cells10123453 · Cited by 33
Foss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 32
Hyperprolactinemia and insulin resistance
Gierach, M., Bruska-Sikorska, M., Rojek, M., & Junik, R. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0075 · Cited by 36
Russo, M. F., Lembo, E., Mari, A., Angelini, G., Verrastro, O., Nanni, G., Pompili, M., Raffaelli, M., Vecchio, F. M., Bornstein, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa892 · Cited by 28
Lipid Storage, Lipolysis, and Lipotoxicity in Obesity
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_4 · Cited by 32
Ross, L. M., Slentz, C. A., Sudnick, A. M., Huffman, K. M., SHALAUROVA, I. Y., Otvos, J. D., Connelly, M. A., Kraus, V. B., Bales, C. W., Houmard, J. A., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.626142 · Cited by 28
“Previous studies have demonstrated the comparability of LPIR to traditional markers for determining a patient’s insulin resistance state (Mackey et al., 2015; Dugani et al., 2016; Harada et al., 2017; Flores-Guerrero et al., 2019).”
BackgroundMethodMontastier, É., Ye, R. Z., Noll, C., Bouffard, L., Fortin, M., Frisch, F., Phoenix, S., Guérin, B., Turcotte, É. E., Lewis, G. F., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00619.2020 · Cited by 29
Li, X., Liu, J., Zhou, B., Li, Y., Wu, Z., Meng, H., & Wang, G. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab325 · Cited by 29
da Silva, R. S., Mendonça, I. P., de Paiva, I. H. R., de Souza, J. R. B., & Peixoto, C. A. (2023) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2023.2262779 · Cited by 29
“…insulin response (Boden 2011), which pre-clinical and clinical studies have extensively demonstrated to drive the hepatic fat accumulation and the progression of MALSD to more severe forms of liver disease (Yu et al. 2002; Gastaldelli, Gaggini, and DeFronzo 2017; Lotta et al. 2017).”
BackgroundYe, R. Z., Montastier, É., Frisch, F., Noll, C., Allard‐Chamard, H., Gévry, N. Y., Tchernof, A., & Carpentier, A. C. (2023) · iScience · doi:10.1016/j.isci.2023.108692 · Cited by 33
“ISAisassociatedwith invivo systemicandATinsulinresistance(usingADIPO-IR 16,17,102–104 andATIRI 15 ),postprandial plasma NEFA levels, increased NEFA uptake and metabolism in lean organs, and DFA partitioning away from SCAT and toward visceral AT.”
BackgroundBello, O., Mohandas, C., Shojaee‐Moradie, F., Jackson, N., Hakim, O., Alberti, K. G. M. M., Peacock, J. L., Umpleby, A. M., Amiel, S. A., & Goff, L. M. (2019) · Diabetologia · doi:10.1007/s00125-019-4820-6 · Cited by 30
Barbosa, C. M., Figueiredo, V. P., Barbosa, M. A., Cardoso, L. M., & Alzamora, A. C. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519002708 · Cited by 30
Divoux, A., Sándor, K., Bojcsuk, D., Yi, F., Hopf, M. E., Smith, J. S., Bálint, B. L., Osborne, T. F., & Smith, S. R. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa042 · Cited by 26
Usefulness of surrogate markers to determine insulin action in fat cells
Rydén, M., Andersson, D. P., & Arner, P. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0592-9 · Cited by 28
Human White Adipose Tissue Displays Selective Insulin Resistance in the Obese State
Mileti, E., Kwok, K. H. M., Andersson, D. P., Mathelier, A., Raman, A., Bäckdahl, J., Jalkanen, J., Massier, L., Thorell, A., Gao, H., et al. (2021) · Diabetes · doi:10.2337/db21-0001 · Cited by 28
“While this likely depends on several mechanisms, recent data from both animals and humans suggest that reduced insulin sensitivity in adipocytes is an early event in the development of disturbed WAT function and whole-body insulin resistance (2,3).”
BackgroundFlenkenthaler, F., Ländström, E., Shashikadze, B., Backman, M., Blutke, A., Philippou‐Massier, J., Renner, S., de Angelis, M. H., Wanke, R., Blum, H., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.751277 · Cited by 28
Climax, J., Newsome, P. N., Hamza, M., Weissbach, M., Coughlan, D., Sattar, N., McGuire, D. K., & Bhatt, D. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016334 · Cited by 26
Índices para la evaluación de la resistencia a la insulina en individuos mexicanos sin diabetes
Almeda‐Valdés, P., Bello‐Chavolla, O. Y., Caballeros-Barragán, C. R., Gómez‐Velasco, D., Viveros-Ruiz, T., Vargas‐Vázquez, A., & Aguilar-Salinas, C. A. (2018) · Gaceta Médica de México · doi:10.24875/gmm.18004578 · Cited by 30
Ahmed, F., Al‐Habori, M., Al-Zabedi, E., & Saif-Ali, R. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00788-5 · Cited by 26
Xu, C., Song, G., Hu, D., Li, G., Liu, Q., & Tang, X. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac140 · Cited by 26
Development of a three‐dimensional in vitro co‐culture model to increase drug selectivity for humans
Park, S. B., Koh, B., Jung, W. H., Choi, K. J., Na, Y. J., Yoo, H. M., Lee, S., Kang, D., Lee, D., & Kim, K. Y. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14033 · Cited by 27
Circulating prolactin level is increased in metabolically healthy obesity
Liu, J., Zhang, L., Fu, J. H., Wang, Q., & Wang, G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0040 · Cited by 30
Youth with type 2 diabetes have hepatic, peripheral, and adipose insulin resistance
Cree‐Green, M., Wiromrat, P., Stuppy, J. J., Thurston, J. E., Bergman, B. C., Baumgartner, A., Bacon, S. D., Scherzinger, A. L., Pyle, L. L., & Nadeau, K. J. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2018 · Cited by 26
Li, F., Ye, J., Sun, Y., Lin, Y., Wu, T., Shao, C., Ma, Q., Liao, X., Feng, S., & Zhong, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0039 · Cited by 24
“Additionally, the fasting adipose tissue insulin resistance (Adipo-IR) index was calculated with the equation FFA (mmol/L)×FINS (pmol/L) [15].”
MethodSun, J., Wang, N., Li, S., Li, M., Zhang, A., Qin, B., Bao, Q., Cheng, B., Cai, S., Wang, S., et al. (2023) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2023-220664 · Cited by 28
“35 36 At the same time, IR is also related to endothelial dysfunction 37 and a pro-oxidative, proinflammatory and procoagulation environment.”
BackgroundRydén, M., Petrus, P., Andersson, D. P., Medina‐Gómez, G., Escasany, E., Corrales, P., Dahlman, I. A., Kulyté, A., & Arner, P. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12887 · Cited by 24
Insulin sensitivity depends on the route of glucose administration
Mingrone, G., Panunzi, S., Gaetano, A. D., Ahlin, S., Spuntarelli, V., Bondia‐Pons, I., Barbieri, C., Capristo, E., Gastaldelli, A., & Nolan, J. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05157-w · Cited by 24
Self-citationCyr, Y., Bissonnette, S., Lamantia, V., Wassef, H., Loizon, E., Sock, E. T. N., Vidal, H., Mayer, G., Chrétien, M., & Faraj, M. (2020) · Obesity · doi:10.1002/oby.22985 · Cited by 24
Dupuit, M., Chavanelle, V., Chassaing, B., Pérrière, F., Etienne, M., Plissonneau, C., Boscaro, A., Barnich, N., Pialoux, V., Maugard, T., et al. (2021) · Nutrients · doi:10.3390/nu13051569 · Cited by 26
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
Khandelwal, R., Dassanayake, A. S., Conjeevaram, H. S., & Singh, S. P. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1479 · Cited by 29
Exercise in the Prevention and Treatment of Type 2 Diabetes
Kirwan, J. P., Heintz, E. C., Rebello, C. J., & Axelrod, C. L. (2023) · Wiley eBooks · doi:10.1002/cphy.c220009 · Cited by 26
James, D., Umekwe, N., Edeoga, C., Nyenwe, E., & Dagogo-Jack, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154263 · Cited by 23
“Keywords Hyperinsulinemic euglycemic clamp; Clamp reproducibility; Insulin sensitivity; Prediabetes; Longitudinal study; Race/Ethnicity 1.1 INTRODUCTION Insulin resistance (or decreased insulin sensitivity) is a characteristic of diverse medical conditions, including overweight/obesity, physical inactivity, hypertensi…”
BackgroundInfluentialLu, C., Zhu, H., Zhao, D., Zhang, J., Yang, K., Lv, Y., Miao, P., Xu, X., Huang, J., Shao, Z., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.787143 · Cited by 23
“In obese patients, inflammatory factors increase and aggravate insulin resistance (Gastaldelli et al., 2017).”
BackgroundRole of fatty liver in the association between obesity and reduced hepatic insulin clearance
Matsubayashi, Y., Yoshida, A., Suganami, H., Ishiguro, H., Yamamoto, M., Fujihara, K., Kodama, S., Tanaka, S., Kaku, K., & Sone, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.12.003 · Cited by 24
Hakim, O., Bonadonna, R. C., Mohandas, C., Billoo, Z., Sunderland, A., Boselli, L., Alberti, K. G. M. M., Peacock, J. L., Umpleby, A. M., Charles‐Edwards, G., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01809 · Cited by 25
Faraj, M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190124 · Cited by 25
Antipsychotic-Induced Alterations in Lipid Turnover
Pereira, S., Au, E., Agarwal, S. M., Wright, D. C., & Hahn, M. (2023) · Endocrinology · doi:10.1210/endocr/bqad025 · Cited by 24
The Effects of Astaxanthin on Metabolic Syndrome: A Comprehensive Review
Gao, C., Gong, N., Chen, F., Hu, S., Zhou, Q., & Gao, X. (2024) · Marine Drugs · doi:10.3390/md23010009 · Cited by 23
“…reported that during IR, impaired inhibition of lipolysis is associated with glucose intolerance and elevated plasma free fatty acid (FFA) levels [102]. have also been shown to block These events have also been shown to block insulin signaling in skeletal muscle, amplify hepatic gluconeogenesis,…”
Michurina, S. S., Stafeev, I., Podkuychenko, N. V., Sklyanik, I. A., Shestakova, E. A., YAHYAEV, K., YURASOV, A., Ratner, E. I., Menshikov, M. Y., Parfyonova, Y. V., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108410 · Cited by 21
Type 1 innate lymphoid cells are associated with type 2 diabetes
Liu, F., Wang, H., Feng, W., Ye, X., Sun, X., Jiang, C., Chu, X., Zhang, P., Jiang, C., Wang, Y., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.005 · Cited by 21
Carotid Body and Metabolic Syndrome: Mechanisms and Potential Therapeutic Targets
Kim, L. J., & Polotsky, V. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145117 · Cited by 24
Świderska, E., Strycharz, J., Wróblewski, A. M., Czarny, P. L., Szemraj, J., Drzewoski, J., & Śliwińska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147712 · Cited by 22
Calderón-DuPont, D., Torre-Villalvazo, I., & Díaz‐Villaseñor, A. (2022) · Biochimie · doi:10.1016/j.biochi.2022.08.021 · Cited by 25
Bensalem, J., Teong, X. T., Hattersley, K. J., Hein, L. K., Fourrier, C., Liu, K., Hutchison, A. T., Heilbronn, L. K., & Sargeant, T. J. (2023) · GeroScience · doi:10.1007/s11357-023-00884-5 · Cited by 22
“This is because age and obesity positively correlate with insulin resistance [43, 44], which is the inability for cells to respond to changes in insulin [45].”
BackgroundRen, Y., Li, Z., Li, J., Liang, R., Wang, Z., Bai, Y., Yang, Y., Tang, Q., Fu, Y., Zhang, X., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13639 · Cited by 27
Zhang, K., Zhu, H., Wang, L., Yang, H., Pan, H., & Gong, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01372-9 · Cited by 20
Cyr, Y., Lamantia, V., Bissonnette, S., Burnette, M., Besse‐Patin, A., Demers, A., Wabitsch, M., Chrétien, M., Mayer, G., Estall, J. L., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14721 · Cited by 20
“This in time favors β-cell exhaustion, reduced insulin secretion, and hyperglycemia (Faraj, 2020; Gastaldelli et al., 2017).”
BackgroundXu, Y., Ma, X., Pan, X., He, X., Wang, Y., & Bao, Y. (2018) · Liver International · doi:10.1111/liv.14021 · Cited by 19
Guo, Q. H., Wang, X., Ke, J., Hou, X., Shen, G., Li, S., Chen, H., Cui, Q., Yu, J., Luo, Q., et al. (2025) · Food Research International · doi:10.1016/j.foodres.2025.115706 · Cited by 22
Increased liver fat associates with severe metabolic perturbations in low birth weight men
Brøns, C., Thuesen, A. C. B., Elingaard-Larsen, L. O., Justesen, L., Jensen, R. T., Henriksen, N. S., Juel, H. B., Størling, J., Ried‐Larsen, M., Sparks, L. M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1221 · Cited by 18
Wang, M., Li, S., Zhang, X., Li, X., & Cui, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14066 · Cited by 21
“Increased gluconeo-genesis is the primary cause of fasting hyperglycemia 42 .”
BackgroundIncreased Prolactin is an Adaptive Response to Protect Against Metabolic Disorders in Obesity
Liu, J., Wang, Q., Zhang, L., Fu, J., An, Y., Meng, H., & Wang, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.002 · Cited by 19
Gancheva, S., KAHL, S., Herder, C., Straßburger, K., Sarabhai, T., Pafili, K., Szendroedi, J., Schlensak, M., & Roden, M. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01292-7 · Cited by 18
“Adipose tissue insulin resistance was assessed in the fasted state from Adipo-IR, calculated as FFAfasting*insulinfasting, [24, 25] and during the hyperinsulinemiceuglycemic clamp from the percent suppression of FFA concentrations, calculated as [FFAfasting -FFAclamp360 min]*100/FFAfasting [26, 27].”
MethodAdipose organ dysfunction and type 2 diabetes: Role of nitric oxide
Bahadoran, Z., Mirmiran, P., & Ghasemi, A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116043 · Cited by 19
Remchak, M. E., Piersol, K. L., Bhatti, S., Spaeth, A. M., Buckman, J. F., & Malin, S. K. (2021) · Nutrients · doi:10.3390/nu13051708 · Cited by 20
“In turn, adipose tissue is responsible for roughly 10–20% of whole-body glucose utilization through influences on insulin signaling [29,30].”
BackgroundZhang, J., Li, M., Wang, T., Tian, W., Ju, J., & Xu, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1523731 · Cited by 16
“Adipose tissue contributes to insulin resistance by releasing free fatty acids (FFA), and elevated plasma FFA levels enhance hepatic gluconeogenesis, impairing glucose-stimulated insulin responses (40).”
Identification of Digestive Enzyme Inhibitors from Ludwigia octovalvis (Jacq.) P.H.Raven
Morales-Ferra, D. L., Ramírez, G., Herrera-Arellano, A., Tortoriello, J., Zavala-Sánchez, M. Á., & Zamilpa, A. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8781352 · Cited by 17
Relation of adipose tissue insulin resistance to prediabetes
Wen, J., Cai, X., Zhang, J., Jiang, J., Li, W., Liu, G., Wang, M., Gaisano, H. Y., Pan, Y., & He, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02186-8 · Cited by 23
“Two recent studies directly demonstrated that the degree of adipose tissue insulin resistance increase in obesity, prediabetes and type 2 diabetes in both the young [18] and adults [19].”
BackgroundRossi, A., Eid, M., Dodgson, J., Davies, G., Musiał, B., Wabitsch, M., Church, C., & Hornigold, D. C. (2020) · Adipocyte · doi:10.1080/21623945.2020.1798613 · Cited by 16
Kitaoka, K., Tsuboi, A., Minato-Inokawa, S., Honda, M., Takeuchi, M., Yano, M., Kurata, M., Wu, B., Kazumi, T., & Fukuo, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001686 · Cited by 15
Bissonnette, S., Saint-Pierre, N., Lamantia, V., Leroux, C., Provost, V., Cyr, Y., RABASA-LHORET, R. P. R., & Faraj, M. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy070 · Cited by 16
Bello, O., Ladwa, M., Hakim, O., Marathe, C. S., Shojaee‐Moradie, F., Charles‐Edwards, G., Peacock, J. L., Umpleby, A. M., Amiel, S. A., & Goff, L. M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0636 · Cited by 15
Mao, Q., Liu, N., Xiong, T., Wang, X., Tian, X., & Kong, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1562135 · Cited by 15
RetractedRole of Nrf2 in Oxidative and Inflammatory Processes in Obesity and Metabolic Diseases
Bayliak, M. M., & Abrat, O. (2020) · Progress in inflammation research · doi:10.1007/978-3-030-44599-7_7 · Cited by 16
CagriSema and the link between obesity and type 2 diabetes
Apovian, C. M., & McDonnell, M. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01291-6 · Cited by 15
Cade, W. T., Mittendorfer, B., Patterson, B. W., Haire-Joshu, D. L., Cahill, A. G., Stein, R. I., Schechtman, K. B., Tinius, R. A., Brown, K. M., & Klein, S. (2022) · Obesity · doi:10.1002/oby.23533 · Cited by 14
Louis, F., Sowa, Y., Kitano, S., & Matsusaki, M. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.020 · Cited by 19
Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid
Kutoh, E., Kuto, A. N., Akiyama, M., Ozawa, E., & Kurihara, R. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03506-3 · Cited by 13
Majid, H., Kohli, S., Islam, S. U., & Nidhi (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01597-6 · Cited by 14
Levine, J. A., Sarrafan‐Chaharsoughi, Z., Patel, T. P., Brady, S. M., Chivukula, K. K., Miller, E. K., Han, J. M., Periwal, V., Wolska, A. T., Remaley, A. T., et al. (2022) · Obesity · doi:10.1002/oby.23341 · Cited by 15
Dou, J., Puttabyatappa, M., Padmanabhan, V., & Bakulski, K. M. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111137 · Cited by 14
Wei, Y., Liu, J., Wang, G., & Wang, Y. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00549-0 · Cited by 15
Obesity and Risk for Lymphoma: Possible Role of Leptin
Jiménez‐Cortegana, C., Hontecillas‐Prieto, L., García-Domínguez, D. J., Zapata, F., Carrión, N. P., Sánchez-León, M. L., Tami, M., Pérez‐Pérez, A., Sánchez-Jiménez, F., Vilariño‐García, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415530 · Cited by 14
Kondeti, S., Dinesh Yadav, D. M., Muralidhar, M. N., Prasad, S. M. V. K., Nemani, H., & Kalashikam, R. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111252 · Cited by 12
Sasaki, N., Maeda, R., Ozono, R., Yoshimura, K., Nakano, Y., & Higashi, Y. (2022) · Diabetes Care · doi:10.2337/dc21-2554 · Cited by 11
Chen, Z., Huang, C., Zhou, Z., Zhang, Y., Xu, M., Tang, Y., Fan, L., & Feng, K. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.1101276 · Cited by 12
Malaikah, S., Willis, S. A., Henson, J. J., Sargeant, J. A., Yates, T. E., Thackray, A. E., Goltz, F. R., Roberts, M. J., Bodicoat, D. H., Aithal, G. P., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01350-0 · Cited by 16
Liu, R., Li, Z., Zhang, Y., Du, M., Wang, X., Shi, Z., & Li, C. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s481233 · Cited by 11
“Adipo-IR 14 was calculated as FINS (μ U/mL) ×free fatty acid (FFA) (mmol/L).”
MethodMetabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
Self-citationImpact of microRNA Regulated Macrophage Actions on Adipose Tissue Function in Obesity
Matz, A., Qu, L., Karlinsey, K. S., & Zhou, B. (2022) · Cells · doi:10.3390/cells11081336 · Cited by 15
“Obese patients with WAT-IR have increased insulin-secreting beta-cell dysfunction, a precursor to Type 2 diabetes mellitus (T2D) [75].”
BackgroundBourebaba, L., Kępska, M., Qasem, B., Zyzak, M., Łyczko, J., Klemens, M., Mularczyk, M., & Marycz, K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1214961 · Cited by 14
Becattini, B., Molinaro, A., Henricsson, M., Borén, J., & Solinas, G. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114132 · Cited by 12
Chen, L., Zhang, Y., Chen, H., Zhang, X., Liu, X., He, Z., Cong, P., Chen, Y., & Mo, D. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00856 · Cited by 12
Cardiovascular disease risk factors and anthropometry features among seemingly healthy young adults
Kalanjati, V. P., Oktariza, R. T., Suwito, B. E., Pradana, K. A., Rahmawan, D., & Abdurachman, A. (2021) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v10i1.20554 · Cited by 11
Sasaki, N., Maeda, R., Ozono, R., Nakano, Y., & Higashi, Y. (2021) · Clinical Obesity · doi:10.1111/cob.12496 · Cited by 11
Samms, R. J., Cheng, C., Fourcaudot, M. J., Heikkinen, S., Khattab, A., Adams, J. M., Cersósimo, E., Triplitt, C. L., PUCKETT, C. L., Tsintzas, K., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00050.2022 · Cited by 11
Self-citationShiri, H., Fallah, H., Abolhassani, M., Fooladi, S., Karim, Z. R., Danesh, B., & Abbasi-Jorjandi, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306977 · Cited by 13
The color of fat and its central role in the development and progression of metabolic diseases
Gaggini, M., Carli, F., & Gastaldelli, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0060 · Cited by 12
Self-citationPuttabyatappa, M., Ciarelli, J. N., Chatoff, A. G., Singer, K., & Padmanabhan, V. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110691 · Cited by 10
Thiab, S., Azeez, J. M., Anala, A. D., Nanda, M., Khan, S., Butler, A. E., & Nandakumar, M. (2025) · Cells · doi:10.3390/cells14151188 · Cited by 12
“Adipose tissue releases adipokines, inflammatory factors, and free fatty acids [137,138] and has a primary function of glucose metabolism.”
Hoffmann, K., Michalak, M., & Paczkowska, A. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s531697 · Cited by 11
Kansal, R., Sharma, V., Potraje, P., & Datta, M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07805-y · Cited by 14
“These fatty acids accumulate in the liver and muscle, further compromising insulin sensitivity [149]. m6A modification is essential for proper adipose tissue development, regulating both stem cell differentiation into preadipocytes and adipocyte maturation.”
Prapa, I., Yanni, A. E., Nikolaou, A., Kostomitsopoulos, N. G., Kalogeropoulos, N., Bezirtzoglou, E., Karathanos, V. Τ., & Kourkoutas, Y. (2022) · Applied Sciences · doi:10.3390/app12094606 · Cited by 10
Solas, M., Zamarbide, M., Ardanaz, C. G., Ramírez, M. J., & Pérez‐Mediavilla, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113591 · Cited by 10
Reduced Growth Hormone Predicts Worsening Adipose Tissue Insulin Resistance in Adults with Obesity
Li, X., Zhou, B., Yao, Y., Wang, G., & Meng, H. (2023) · Obesity Facts · doi:10.1159/000530734 · Cited by 11
Metadata
- Authors
- Gastaldelli, A., Gaggini, M., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Gastaldelli, Amalia
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-01-04
- Volume
- 66
- Issue
- 4
- Pages
- 815-822
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2571158149
- Cited by
- 344
- References
- 41
- Citations by year
- 2026: 20 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 46 · 2021: 62 · 2020: 43 · 2019: 28 · 2018: 25 · 2017: 6
- FWCI
- 21.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- EU Horizon 2020 project EpoS (634413)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- adipose tissue insulin resistance, type 2 diabetes, impaired glucose tolerance, beta-cell function, free fatty acids, insulin resistance, obesity, glucose tolerance, Matsuda index
- MeSH terms
- Adipose Tissue, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Obesity, Glucose Clamp Technique, Case-Control Studies, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.